Session » Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

Date: Saturday, November 16, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 0343

An Interlaboratory Variability Study of Detection Methods for Myositis-Specific and Myositis-Associated Autoantibodies in Sera from Patients with Idiopathic Inflammatory Myopathies

10:30AM-12:30PM: Abstract Number: 0335

Analysis of the Prevalence of Diabetes Mellitus in Patients with Adult-onset Dermatomyositis

10:30AM-12:30PM: Abstract Number: 0338

Anti-MDA5 Antibody-positive Dermatomyositis Associated Interstitial Lung Disease – Survival Benefit of Treatment with Rituximab, Janus Kinase Inhibitor and Glucocorticoid Combination in a Prospective Cohort

10:30AM-12:30PM: Abstract Number: 0330

Baseline Interstitial Lung Disease (ILD) Characteristics and Outcomes in Patients with Anti-synthetase Syndrome Related ILD (ASSD-ILD): Analysis from the “Classification Criteria for Anti-synthetase Syndrome (CLASS)” Project Database

10:30AM-12:30PM: Abstract Number: 0331

Cardiac Manifestations in Patients with Anti-Synthetase Syndrome: Analysis from the “Classification Criteria for Anti-synthetase Syndrome (CLASS)” Project Database

10:30AM-12:30PM: Abstract Number: 0344

Characteristics of Patients with Antisynthetase Antibodies

10:30AM-12:30PM: Abstract Number: 0337

Characterization of Statin Induced Myopathy in the Hospital Setting

10:30AM-12:30PM: Abstract Number: 0327

Clinical and Immunological Risk Factors Associated with Fybromialgia in Patients with Idiopathic Inflammatory Myopathies

10:30AM-12:30PM: Abstract Number: 0339

Clinical Characteristics Associated with Inpatient Mortality in Dermatomyositis Patients: A Single Center Retrospective Cohort Study

10:30AM-12:30PM: Abstract Number: 0346

Clonally Expanded and Total B Cells in Patients with Idiopathic Inflammatory Myopathies Show Skewed B Cell Subset Distribution and Reduced Somatic Hypermutation Relative to Healthy Controls

10:30AM-12:30PM: Abstract Number: 0320

Comparative Transcriptional Profiling Reveals Shared Pathway Activation Between Human Jo-1+ Anti-Synthetase Syndrome and Murine Histidyl-tRNA Synthetase-Induced Myositis

10:30AM-12:30PM: Abstract Number: 0324

Correlative Studies of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-MyositisTM and RESET-SLETM Clinical Trials

10:30AM-12:30PM: Abstract Number: 0347

Dermato-polymyositis Mortality in U.S. Population: Declining Cancer and Cardiovascular Diseases Among the Leading Underlying Causes of Death over Two Decades

10:30AM-12:30PM: Abstract Number: 0321

Diffusion Weighted Imaging in Muscle MRI Can Detect Quantitative Improvements in Muscle Edema: A Post-hoc Analyses of the Study of Tofacitinib in Refractory Dermatomyositis

10:30AM-12:30PM: Abstract Number: 0341

Efficacy and Safety of Nintedanib in Patients with Idiopathic Inflammatory Myopathy-related Interstitial Lung Disease

10:30AM-12:30PM: Abstract Number: 0322

Enhanced Detection of Myocarditis in Idiopathic Inflammatory Myopathies Utilizing Multiparametric Cardiac Magnetic Resonance Imaging

10:30AM-12:30PM: Abstract Number: 0328

IFI27 Is Differentially Upregulated in Anti-MDA5 Dermatomyositis and Correlates with the Presence of Interstitial Lung Disease

10:30AM-12:30PM: Abstract Number: 0342

Measurement of Serum Cytokine and Chemokine Level to Predict Poor Treatment Response in Patients with Idiopathic Inflammatory Myositis

10:30AM-12:30PM: Abstract Number: 0336

Mortality: Comparison, Causes and Determinants in Subgroups of Idiopathic Inflammatory Myopathies

10:30AM-12:30PM: Abstract Number: 0334

Normal Creatine Kinase in Idiopathic Inflammatory Myopathies- Patient Characteristics and Disease Activity

10:30AM-12:30PM: Abstract Number: 0323

Pain Prevalence and Factors Associated with Pain Levels in Patients with Idiopathic Inflammatory Myopathies

10:30AM-12:30PM: Abstract Number: 0332

Predictors of Long-term Radiographic Changes in Patients with Idiopathic Inflammatory Myopathies Using Quantitative Imaging Analysis: Real World Experience from a Single Center Longitudinal Cohort

10:30AM-12:30PM: Abstract Number: 0333

Predictors of Transplant-Free Survival in Idiopathic Inflammatory Myopathies- associated Interstitial Lung Disease

10:30AM-12:30PM: Abstract Number: 0340

Progressive Pulmonary Fibrosis Predicts Mortality in Myositis-Associated Interstitial Lung Disease

10:30AM-12:30PM: Abstract Number: 0329

Racial, Ethnic, Sex, and Geographical Diversity in Myositis Clinical Trials: Future Steps for Equitable Representation by the MIHRA Global Equity and Clinical Trial Readiness Cores

10:30AM-12:30PM: Abstract Number: 0319

Sporadic Inclusion Body Myositis Novel Autoantibody and Biomarker Research Utilizing Proteome Microarray and Mass Spectrometry Proteomics Analysis

10:30AM-12:30PM: Abstract Number: 0325

The Impact of Polymyositis and Dermatomyositis in Patients Hospitalized with Inflammatory Bowel Disease: A Nationwide Inpatient Database Analysis

10:30AM-12:30PM: Abstract Number: 0345

Treatment Patterns and Glucocorticoid Burden of Dermatomyositis Patients: A Cohort Study in the University of Pittsburgh’s Myositis Registry

10:30AM-12:30PM: Abstract Number: 0348

Upadacitinib in Interstitial Lung Disease Associated with Idiopathic Inflammatory Myopathies

10:30AM-12:30PM: Abstract Number: 0326

Validity and Responsiveness of Core Set Measures in Idiopathic Inflammatory Myositis Based on 36-item Short Form Health Survey (SF-36)

« View all sessions from this meeting